Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

239
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
239
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

182
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
182
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

149
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
149
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

283
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
283
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

308
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
308
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

169
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
169

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Multicenter cohort analysis of cardiac amyloidosis patients treated with heart transplant.

Revista espanola de cardiologia (English ed.)·2026
Same author

Natural Language Processing Framework in Early Detection of Amyloidosis: The ALARM Study.

JACC. Advances·2026
Same author

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

JACC. CardioOncology·2026
Same author

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

JAMA cardiology·2026
Same author

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal of cardiac failure·2026

Video Experimental Relacionado

Updated: Dec 10, 2025

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.8K

Mavacamten para el tratamiento de la miocardiopatía hipertrófica sintomática (EXPLORER- HCM): ensayo aleatorizado,

Iacopo Olivotto1, Artur Oreziak2, Roberto Barriales-Villa3

  • 1Cardiomyopathy Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; University of Florence, Florence, Italy.

Lancet (London, England)
|September 2, 2020
PubMed
Resumen
Este resumen es generado por máquina.

Mavacamten mejoró significativamente la capacidad de ejercicio y redujo la obstrucción del tracto de flujo ventricular izquierdo en pacientes con miocardiopatía hipertrófica obstructiva. Este inhibidor cardíaco de la miosina ofrece una opción de tratamiento específica de la enfermedad con buena tolerabilidad.

Más Videos Relacionados

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

4.3K
Minimally Invasive Transverse Aortic Constriction in Mice
07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

21.3K

Videos de Experimentos Relacionados

Last Updated: Dec 10, 2025

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.8K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

4.3K
Minimally Invasive Transverse Aortic Constriction in Mice
07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

21.3K

Área de la Ciencia:

  • Cardiología
  • Farmacología
  • La genética

Sus antecedentes:

  • La hipercontractilidad del músculo cardíaco conduce a la cardiomiopatía hipertrófica (HCM) y la obstrucción del tracto de salida ventricular izquierda (LVOT).
  • Los tratamientos farmacológicos actuales para la HCM son inadecuados, mal tolerados y no son específicos de la enfermedad.

Objetivo del estudio:

  • Evaluar la eficacia y seguridad de mavacamten, un nuevo inhibidor de la miosina cardíaca, en pacientes con CMH obstructiva sintomática.

Principales métodos:

  • Un ensayo de fase 3, aleatorizado, doble ciego, controlado con placebo (EXPLORER- HCM) incluyó a 251 pacientes con HCM obstructiva.
  • Los pacientes recibieron mavacamten o placebo durante 30 semanas, con evaluaciones que incluyeron ecocardiografía, pVO2 y clase NYHA.

Principales resultados:

  • Mavacamten mejoró significativamente el consumo máximo de oxígeno (pVO2) y redujo el gradiente LVOT en comparación con el placebo.
  • Los pacientes tratados con mavacamten mostraron una mayor mejora en las puntuaciones de clase NYHA y calidad de vida (KCCQ-CSS, HCMSQ-SoB).
  • La seguridad y tolerabilidad de mavacamten fueron comparables a las del placebo, con eventos adversos generalmente leves.

Conclusiones:

  • El tratamiento con Mavacamten demostró beneficios significativos en la capacidad de ejercicio, la obstrucción de LVOT y el estado funcional de los pacientes con CMH obstructiva.
  • Este estudio apoya mavacamten como una opción terapéutica específica de la enfermedad para la miocardiopatía hipertrófica obstructiva.